Planned 8,480-share sale by Ionis (NASDAQ: IONS) under Rule 144 stock

Rhea-AI Filing Summary

Ionis Pharmaceuticals has a planned insider sale of 8,480 shares of its common stock under Rule 144. The shares are expected to be sold through Morgan Stanley Smith Barney on or about January 16, 2026, with an aggregate market value of $646,375.84, on the NASDAQ exchange.

The securities were acquired on January 15, 2026 as RSUs granted under the company’s 2011 Equity Incentive Plan, classified as compensation. The filing notes that 161,137,930 shares of common stock were outstanding, giving context for the size of this planned transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	8480	646375.84	161137930	01/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			8480	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Ionis (IONS) disclose?

The Form 144 discloses a planned sale of 8,480 shares of Ionis Pharmaceuticals common stock under Rule 144, to be executed through Morgan Stanley Smith Barney on or about January 16, 2026.

How many Ionis (IONS) shares are planned to be sold and what is their value?

The filing indicates a planned sale of 8,480 common shares of Ionis Pharmaceuticals, with an aggregate market value of $646,375.84.

How were the Ionis (IONS) shares being sold under Form 144 acquired?

The shares were acquired on January 15, 2026 as RSUs granted under Ionis Pharmaceuticals’ 2011 Equity Incentive Plan, categorized as compensation.

On which exchange will the Ionis (IONS) shares be sold and through which broker?

The planned sale is to take place on the NASDAQ exchange, with Morgan Stanley Smith Barney acting as the broker for the transaction.

How many Ionis (IONS) shares were outstanding in relation to this planned sale?

The filing reports that 161,137,930 shares of Ionis Pharmaceuticals common stock were outstanding, providing context for the 8,480-share planned sale.

What type of securities are covered in this Ionis (IONS) Form 144?

The Form 144 covers common stock of Ionis Pharmaceuticals that is planned to be sold under Rule 144, following acquisition as RSU compensation.